Asarina Pharma Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Asarina Pharma
Access all reports
Asarina Pharma AB is a Swedish biotechnology company specializing in the development of Sepranolone, a compound designed to treat stress, compulsivity, and neurological disorders related to Allopregnanolone. This neurosteroid is implicated in conditions such as Tourette syndrome, Obsessive-Compulsive Disorder (OCD), and Premenstrual Dysphoric Disorder (PMDD). Asarina Pharma's focus is on innovative treatments that modulate the effects of Allopregnanolone, aiming to provide safer and more effective therapeutic options. The company is headquartered in Solna, Sweden, and its shares are listed on the Nasdaq Stockholm.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
ASAP
Country
🇸🇪 Sweden